On Wednesday, Shares of Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF), gain 29.70% to $5.24.
Can Fite Biopharma declared that it has reached definitive agreements with institutional investors to receive gross proceeds of $9 million.
In connection with the offering, the Company will issue 2,068,966 registered American Depository Shares (ADSs) of Can-Fite at a purchase price of $4.35 per ADS in a registered direct offering. Additionally, for each ADS purchased by investors, the investors will receive an unregistered warrant to purchase one-half of an ADS. The warrants have an exercise price of $5.25 per ADS, shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The closing of the offering is predictable to take place on or about September 23, 2015, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. acted as the exclusive placement agent in connection with this offering.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Shares of Merck & Co., Inc. (NYSE:MRK), inclined 0.57% to $51.03, during its last trading session.
Merck & Co., known as MSD outside the United States and Canada, declared recently that new data investigating the anti-tumor activity of KEYTRUDA® (pembrolizumab) across a broad range of advanced cancers will be presented at this year’s European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this year’s ECC – counting four late-breaking oral presentations. First-time data looking at PD-L2 expression in multiple tumors to assess the potential value of this biomarker in patient responsiveness to anti PD-1 therapies will also be presented. With these and other presentations, data on the potential role of KEYTRUDA will have been presented in more than 17 different cancers.
Studies accepted into this year’s ECC program also comprise the investigation of KEYTRUDA monotherapy in anal cancer, biliary tract cancer, colorectal cancer, Merkel cell carcinoma (a type of skin cancer), nasopharyngeal carcinoma (a type of head and neck cancer), and non-small cell lung cancer (NSCLC), in addition to a study evaluating KEYTRUDA in combination with another immunotherapy treatment in melanoma.
KEYTRUDA, Merck’s anti-PD-1 therapy, is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, counting the anti-tumor immune response. The KEYTRUDA clinical development program has rapidly expanded to encompass more than 30 tumor types in more than 130 clinical trials, of which more than 70 trials combine KEYTRUDA with other cancer treatments. Registration-enabling trials of KEYTRUDA monotherapy are presently enrolling patients in melanoma, NSCLC, head and neck cancer, bladder cancer, gastric cancer, colorectal cancer, and Hodgkin Lymphoma, with further trials in planning for other cancers.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures.
Shares of Charles Schwab Corp (NYSE:SCHW), inclined 0.60% to $28.50, during its last trading session.
Charles Schwab Corp released its Monthly Activity Report recently. Company highlights for the month of August 2015 comprise:
- Net new assets brought to the company by new and existing clients in August 2015 totaled $9.2 billion.
- Total client assets were $2.46 trillion as of month-end August, up 1% from August 2014 and down 4% contrast to July 2015.
- Average interest-earning assets on the company’s balance sheet were a record $160.6 billion in August, up 16% from August 2014 and up 2% contrast to July 2015.
The Charles Schwab Corporation (CSC) is a savings and loan holding company. Through its auxiliaries, the Company engages in wealth administration, securities brokerage, banking, money administration and financial advisory services. The Company provides financial services to individuals and institutional clients through two segments: Investor Services and Advisor Services.
Finally, Noble Energy, Inc. (NYSE:NBL), ended its last trade with -1.36% loss, and closed at $31.87.
Noble Energy, will host its third quarter 2015 results webcast and conference call at 9:00 a.m., Central Time, on Monday, November 2, 2015. The Company plans to issue its financial and operating results, counting supporting presentation materials for the conference call, before the market opening on the same day.
Noble Energy, Inc. is an independent energy company engaged in crude oil, natural gas and natural gas liquids exploration and production. Its operations are grouped into four components: the United States; West Africa (Equatorial Guinea, Cameroon, Gabon and Sierra Leone; Eastern Mediterranean (Israel and Cyprus), and Other International and Corporate.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
